Senate Finance Committee Advances Klomp for HHS Deputy Role Amid Tax and Vaccine Disputes

Key points

• Senate Finance Committee voted 15-12 to recommend Chris Klomp for HHS deputy secretary, with all Republicans and Senator Sheldon Whitehouse (D-R.I.) in support.
• Klomp is currently leading negotiations for the most-favored-nation drug pricing program and helped select CDC director Erica Schwartz.
• Klomp endorsed the measles, mumps, and rubella (MMR) vaccine during hearings, stating the ongoing U.S. measles outbreak is a top priority, despite Kennedy’s previous skepticism.
• Senator Ron Wyden (D-Ore.) voted against Klomp, citing his refusal to release details on drug price deals and allegations that Klomp manipulated tax payments to avoid Social Security and Medicare contributions.
• The committee also advanced Ge Bai for HHS assistant secretary (14-13) and Jim Gadwood for IRS chief counsel (14-13), with Gadwood facing questions about regulations targeting university tax exemptions.
• Chair Mike Crapo (R-Idaho) defended Klomp, stating the tax issues are being litigated in court and that Klomp met the committee’s vetting standards.

Background

This development follows a period of intense scrutiny regarding HHS leadership and vaccine policy. In late August 2026, the CDC released a youth risk behavior survey that highlighted nutrition gains but avoided sex-specific mental health trends, reflecting broader tensions within the agency. Earlier in 2026, the administration faced challenges regarding the authorization of flavored vapes and approval standards, leading to the resignation of former FDA Commissioner Marty Makary. The current confirmation process for Klomp and FDA nominee Heidi Overton occurs against a backdrop of ongoing debates over vaccine safety, drug pricing transparency, and the administration’s relationship with pharmaceutical companies. The measles outbreak, which began 19 months ago and has affected nearly 6,000 people, has intensified the political stakes surrounding HHS leadership and public health messaging.

How outlets are covering it

Politico and STAT News both reported the 15-12 vote to advance Klomp, emphasizing his role in drug pricing negotiations and his endorsement of the MMR vaccine. STAT News highlighted that Klomp acknowledged his significant influence over HHS operations and personnel, while noting that Democrats and Senator Bill Cassidy (R-La.) had pressed him to push back against Kennedy and Trump on vaccine policy. Politico detailed the specific criticisms from Senator Ron Wyden, who accused Klomp of manipulating tax payments and withholding details on pharmaceutical deals, contrasting with Chair Mike Crapo’s defense that the tax issues are under litigation. Bloomberg Law News focused on the procedural advancement of Jim Gadwood for IRS chief counsel, noting the 14-13 vote and the broader context of tax court appointments. Politico Pro provided additional context on Gadwood, reporting that Senate Democrats questioned him about regulations proposed to strip tax-exempt status from universities, highlighting concerns about legal authority and enforcement. The outlets differ in focus: Politico and STAT concentrate on the political and policy implications of Klomp’s confirmation, while Bloomberg and Politico Pro emphasize the legal and regulatory aspects of the other nominees advanced by the same committee.

Why it matters

The advancement of Chris Klomp signals a consolidation of power within the HHS leadership under Robert F. Kennedy Jr., potentially influencing drug pricing, vaccine policy, and public health responses to outbreaks like measles. The contentious vote highlights deep divisions within the Senate over transparency in pharmaceutical negotiations and the integrity of tax compliance among high-level officials. Furthermore, the simultaneous advancement of nominees for the IRS and HHS suggests a coordinated effort by the Trump administration to install loyalists in key regulatory positions, which could impact future legislation on healthcare, education, and taxation. The opposition from Democrats, particularly regarding tax evasion and drug deal secrecy, may lead to further scrutiny and potential delays in the full Senate confirmation process.

What to watch

Chris Klomp’s nomination will now move to the full Senate for a final confirmation vote. The outcome may depend on the continued opposition from Democrats like Ron Wyden and the potential for further legal challenges regarding his tax payments. The Senate is also expected to vote on other nominations, including Heidi Overton for FDA commissioner, who faced questions about mifepristone and vaccine safety. Additionally, the Senate may consider votes on the Ratepayer Protection Act and other energy-related bills, as Majority Leader John Thune indicated the chamber would remain in session next week. The legal status of Klomp’s tax maneuvers and the details of the most-favored-nation drug deals will likely remain central issues in the confirmation debate.